Skip to content
Biodatica
Start free

SciClone Pharmaceuticals

Guangzhou

OncologyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

6mo agoTrial registeredDec 31, 2025Source filing (opens the source filing in a new tab)

Momentum

72no change

Momentum 72 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

483 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Aug 18, 2025

    Advanced Breast Cancer · RECRUITING · sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

    ClinicalTrials.gov · NCT07037199 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Aug 1, 2025

    Breast Cancer Metastatic, HR+/HER2- Advanced Breast Cancer · WITHDRAWN · sponsor: SciClone Pharmaceuticals · A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

    ClinicalTrials.gov · NCT07076680 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Jun 12, 2024

    Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer · RECRUITING · sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

    ClinicalTrials.gov · NCT06255392 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources